Platinum Investment Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Platinum Investment Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,020,507	Closed	-$1.35M	–	160
2023 Q1	$1.35M	Sell	1,020,507 -195,460	-16%	-$320K	0.05%	94
2022 Q4	$2.05M	Hold	1,215,967	–	–	0.08%	78
2022 Q3	$2.25M	Hold	1,215,967	–	–	0.09%	72
2022 Q2	$3.73M	Sell	1,215,967 -34,711	-3%	-$212K	0.14%	60
2022 Q1	$9.03M	Buy	1,250,678 +163,608	+15%	+$1.61M	0.28%	46
2021 Q4	$17.8M	Buy	1,087,070 +121,120	+13%	+$1.41M	0.5%	37
2021 Q3	$9.61M	Buy	+965,950	New	+$9.6M	0.27%	45

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Platinum Investment Management's PRDS Position: Q2 2023 in Review

Platinum Investment Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2023, closing a stake of 1,020,507 shares — an estimated $1.35M sold.

Platinum Investment Management first reported a position in PRDS in Q3 2021 and held it in 7 quarters. The position peaked at $17.8M in Q4 2021. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

Platinum Investment Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Platinum Investment Management sold 1,020,507 Pardes Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.35M.
Platinum Investment Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Platinum Investment Management's Pardes Biosciences, Inc. Common Stock position peaked at $17.8M in Q4 2021.
59 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2023.

Based on Platinum Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.